Pharmaceutical

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas.

Apr 23, 2024 - 00:00
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas.
Read the original article

Tags:

Previous Article

Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe My...

Next Article

Datopotamab deruxtecan by Daiichi Sankyo for Head And Neck Squamous Cell Carcino...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Peter Marks on creating Operation Warp Speed, but for rare diseases

STAT+: Peter Marks on creating Operation Warp Speed, bu...

Oct 12, 2023

Opinion: Why isn’t there any enforcement of the ACA mandate to support breastfeeding?

Opinion: Why isn’t there any enforcement of the ACA man...

Sep 2, 2023

ESC 2024: Obesity drugs emerge as attractive tool for heart failure prevention

ESC 2024: Obesity drugs emerge as attractive tool for h...

Aug 31, 2024